Pediatric Hematological Malignancies: Immunotherapy, Causes of Childhood Haematological Cancers, Clinical Manifestation, Treatment and Problems Occurring After Treatment
10.52845/CMRO/2025/8-1-6
Abstract
Cancers that start in the cells of tissues that produce blood, like bone marrow, are known as haematological malignancies. Despite their rarity, blood malignancies continue to top the list of killers among children ages 1–14. Reducing death rates is possible by early discovery, which improves the likelihood of effective treatment. Among youngsters, leukaemias and lymphomas make up over 50% of all new cancer cases. Despite significant progress—the overall survival rate has increased from 10% to about 90% today—the survival rate is significantly lower for many uncommon malignancies. If the mechanisms and genetic abnormalities involved in leukemogenesis can be better understood, tailored therapy has the potential to increase anti-leukemic efficacy while decreasing treatment-related morbidity or mortality. More than 80% of children survive childhood thanks to improvements in the last several decades. Clinical trials carried out by many research groups, including those specialising in paediatrics and oncology, have contributed to these advancements. These were complemented by the substantial contributions made by the discovery of efficient therapeutic agents when combined with different chemotherapeutic drugs. Cure rates for non-lymphoblastic leukaemia have barely reached 50%, despite the overall survival rate of malignancies improving to 90%. Additionally, stem cell transplantation and other intensified regimens have improved outcomes; yet, contemporary therapies are linked to several acute and late complications, and related consequences seem to be on the rise. Haematological cancers can be better treated and patients can have a better chance of survival if our knowledge of the genes and processes that cause them grows. Advances in molecular biology have greatly enhanced our capacity to detect and prevent illness recurrence, monitor how patients react to various treatment plans, make more accurate predictions about their prognoses, and personalise their treatments. In order to develop effective treatments for subsets of children with haematological malignancies, the paediatric oncology and allied research communities must first identify and confirm the most significant therapeutic targets.
Keywords
- Acute myeloid leukemia
- Cancer
- Chemotherapy
- Children
- Cytogenetics
- Etiology
- Genetic abnormalities
- Hematological malignancies
How to Cite
Ghoftan Jwaid Rafea, Zahraa Adnan Auda Alamash , Sajad Abbas Hadi . (2025). Pediatric Hematological Malignancies: Immunotherapy, Causes of Childhood Haematological Cancers, Clinical Manifestation, Treatment and Problems Occurring After Treatment. Journal of Current Medical Research and Opinion , Vol. 8 No. 01 (2025) , 3866-3878 . https://doi.org/10.52845/CMRO/2025/8-1-6